NASDAQ:CLDX 26 February 2026

Celldex Therapeutics (CLDX) stock slips in premarket after 24% rally on Phase 3 barzolvolimab milestone

Celldex Therapeutics shares fell about 4% to $29.58 in premarket trading Thursday, after surging 24% the previous session. The company completed enrollment in two global Phase 3 barzolvolimab studies for chronic spontaneous urticaria six months ahead of schedule. Topline data are expected in Q4 2026, with a U.S. BLA filing planned for 2027. Celldex ended 2025 with $518.6 million in cash and posted a full-year net loss of $258.8 million.

26 February 2026

NASDAQ:CLDX·Pharmaceuticals·Stock Market

Flow Traders Launches 24/7 OTC Liquidity for Tokenized Equities and Commodities
March 19, 2026, 5:11 AM EDT. Flow Traders, a leading market maker in exchange-traded products, introduced a 24/7 over-the-counter (OTC) liquidity service for tokenized stocks, gold, and money market funds. The service, accessible through its Digital Asset OTC platform, offers continuous two-way pricing for tokenized assets like Franklin Templeton's BENJI and tether gold (XAUT). It targets institutional clients, enabling risk management and capital flow during weekends and after-hours when traditional markets are closed. The launch addresses a key challenge for institutions needing to adjust positions outside regular market times, bolstered by growing tokenization markets valued at trillions and expanding rapidly. Flow Traders' initiative enhances liquidity for large trades amid developing public market venues, supporting broader access and efficient trading in the digital asset space.